Add like
Add dislike
Add to saved papers

The primary neuronal cells are more resistant than PC12 cells to α-synuclein toxic aggregates.

Neuroscience Letters 2019 Februrary 16
BACKGROUND: Alpha-synuclein (αSN) is an abundant presynaptic brain protein that its aggregated species believed to play pivotal roles in the development of neurodegenerative diseases, especially Parkinson's disease (PD). In this study, we compared the response of primary neuronal cells with a well-known cell line model, PC12, against the toxic aggregates of αSN.

METHODS: Primary hippocampal neurons (PHNs) were isolated from 17 to 18 days old rat embryos. Fibrillization was induced in recombinant αSN and monitored by standard methods. The toxicity of different aggregates of αSN on the treated cells was then studied. Furthermore, changes in the intracellular reactive oxygen species (ROS) and Ca2+ levels were also compared in two kinds of treated cells. We also studied the gene expression profile of certain Ca2+ channels and carriers using the GEO2 database.

RESULTS: The viability rate was significantly lower in PC12 versus PHNs, in response to αSN. This is while the intracellular ROS and Ca2+ levels were significantly increased in both cell types. Analysis of microarray data indicated that some factors involved in Ca2+ hemostasis may face significant changes in the PD condition.

CONCLUSION: By putting these data together, it is clear that PHN is more resistant than PC12 toward αSN cytotoxicity even in the presence of rising cytoplasmic ROS and Ca2+ levels. Exploring the supporting mechanisms which PHN uses to be more resistant to αSN cytotoxicity can help to open a roadmap toward therapeutic plans in PD and other synucleinopathy disorders.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app